The company said the results of a planned interim analysis met prespecified criteria for early termination of the study. "They did not meet the high-bar efficacy we established for advancing our ...
Johnson & Johnson said on Friday it discontinued a mid-stage study of its experimental drug to treat patients with moderate ...
A new study published in the journal of Inflammopharmacology showed that in individuals with moderate-to-severe atopic ...
The top 5 most-read dermatology content of 2025 on AJMC.com included innovative advances from artificial intelligence ...
Johnson & Johnson has discontinued a phase 2 trial of one of its pipeline candidates for atopic dermatitis (AD), after it ...
Gadgets are now a part of the everyday routine for us. Tablets, phones, and laptops not only tend to affect the posture and ...
HealthDay News — Iron deficiency without anemia is a common feature of moderate-to-severe atopic dermatitis (AD), according to a study published in Nutrients.
Seborrheic dermatitis is associated with other epithelial barrier diseases of the skin and beyond, including the respiratory, ...
Nemolizumab, which targets the interleukin-31 pathway, rapidly improves itch and sleep in people with atopic dermatitis and ...
Dermatitis herpetiformis is a bumpy, very itchy skin rash that’s caused by gluten sensitivity. In fact, about 10%-25% of people with celiac disease get dermatitis herpetiformis. Celiac disease is an ...
A new study from North Carolina State University found that neutrophils—white blood cells that are a key part of the immune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback